Beta Bionics Q3 adjusted EBITDA misses estimates
Overview
US diabetes device maker's Q3 net sales rose 30%, beating analyst expectations
Q3 adjusted EBITDA missed analyst estimates; operating loss was a slight miss
Outlook
Beta Bionics raises 2026 revenue guidance to $124 mln-$126 mln from $121 mln-$126 mln
Company expects up to $8.5 mln in Q4 2026 revenue deferral as customers await Mint launch
Beta Bionics expects Mint to recapture any lost Q4 2026 revenue during 2027
Result Drivers
PBP CHANNEL GROWTH - Co said Pharmacy Benefit Plan channel net sales rose 118% year-on-year, driving overall sales growth
NEW PATIENT STARTS - Co reported mid-single digit percentage increase in new patient starts versus prior quarter
GROSS MARGIN IMPROVEMENT - Co said gross margin rose 179 basis points year-on-year to 57.3%
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net sales | Beat | $35.51 mln | $34.72 mln (14 Analysts) |
Q3 Loss Per Share | $0.52 | ||
Q3 Net Loss | $24.35 mln | ||
Q3 Adjusted EBITDA | Miss | -$18.91 mln | -$18.46 mln (10 Analysts) |
Q3 Income from Operations | Slight Miss* | -$26.61 mln | -$26.42 mln (13 Analysts) |
Q3 Gross Profit | $20.33 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Beta Bionics, Inc. is $25.00, about 21.9% above its October 26 closing price of $20.51
Reuters Recommended Reads
Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss
Oct 26 - Medifast Q3 revenue falls on fewer active earning coaches
Oct 27 - FDA warns Amgen over cancer drug promotional video
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)